$328 Million is the total value of Opaleye Management Inc.'s 43 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 71.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMY | Buy | HARROW HEALTH | $19,227,000 | +114.5% | 2,210,000 | +22.8% | 5.86% | +136.1% |
| ODT | Buy | ODONATE THERAPEUTICS INC | $15,593,000 | +117.0% | 425,000 | +30.8% | 4.75% | +138.8% |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $12,980,000 | +72.1% | 2,950,000 | +55.3% | 3.96% | +89.4% |
| PTCT | Buy | PTC THERAPEUTICS INC | $10,187,000 | +26.6% | 226,388 | +5.9% | 3.10% | +39.4% |
| Buy | CYTOKINETICS | $10,125,000 | +47.2% | 900,000 | +5.9% | 3.09% | +62.1% | |
| EIDX | Buy | EIDOS THERAPEUTICS INC | $9,496,000 | +102.5% | 305,550 | +52.8% | 2.89% | +122.8% |
| LXRX | New | LEXICON PHARMACEUTICALS INC | $9,309,000 | – | 1,480,000 | +100.0% | 2.84% | – |
| ETON | Buy | ETON PHARMACEUTICALS INC | $8,493,000 | +38.8% | 1,075,000 | +40.6% | 2.59% | +52.8% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $7,891,000 | -6.1% | 535,000 | +4.9% | 2.40% | +3.4% |
| TCDA | Buy | TRICIDA INC | $7,695,000 | +20.8% | 195,000 | +18.2% | 2.34% | +32.9% |
| BHVN | New | BIOHAVEN PHARMACEUTICAL HLDG | $6,569,000 | – | 150,000 | +100.0% | 2.00% | – |
| CMRX | Buy | CHIMERIX INC | $6,350,000 | +215.0% | 1,470,000 | +53.1% | 1.94% | +246.8% |
| ATXI | Buy | AVENUE THERAPEUTICS INC | $5,859,000 | +54.2% | 930,000 | +16.2% | 1.79% | +69.8% |
| IRWD | New | IRONWOOD PHARMACEUTICAL INC | $5,748,000 | – | 525,400 | +100.0% | 1.75% | – |
| ARVN | New | ARVINAS INC | $4,838,000 | – | 220,000 | +100.0% | 1.48% | – |
| VRML | New | VERMILLION INC | $3,783,000 | – | 4,250,000 | +100.0% | 1.15% | – |
| ZYME | Buy | ZYMEWORKS INC | $3,744,000 | +320.7% | 170,000 | +209.1% | 1.14% | +363.8% |
| Buy | FORTRESS BIOTECH INC | $3,548,000 | -0.3% | 2,365,000 | +18.2% | 1.08% | +9.6% | |
| AQST | New | AQUESTIVE THERAPEUTICS INC | $2,478,000 | – | 590,000 | +100.0% | 0.76% | – |
| THOR | Buy | SYNTHORX INC | $2,129,000 | +161.2% | 157,600 | +294.0% | 0.65% | +187.2% |
| RARX | New | RA PHARMACEUTICALS INC | $1,534,000 | – | 51,000 | +100.0% | 0.47% | – |
| ARQL | New | ARQULE INC | $1,101,000 | – | 100,000 | +100.0% | 0.34% | – |
| PLX | New | PROTALIX BIOTHERAPEUTICS INC | $469,000 | – | 1,000,000 | +100.0% | 0.14% | – |
| AZRX | New | AZURRX BIOPHARMA INC | $247,000 | – | 145,000 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-31 |
| 13F-HR/A | 2024-05-29 |
| 4 | 2024-05-23 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.